Susanta Samajdar

This inventor holds 27 USPTO granted patents and 28 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Aurigene Discovery Technologies Limited, Aurigene Oncology Limited, Novartis Ag. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Susanta Samajdar. Retrieved from https://idiyas.com/inventor/susanta-samajdar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 28)

% Patents Active = 81.5

CIPO Patents = 1 (Patent Applications = 19)

EPO Patents = 10 (Patent Applications = 47)

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 82(Granted Patents)

Location History:

Karnataka, IN (2015 - 2018)
Kamataka, IN (2017 - 2020)
Bengaluru, IN (2017 - 2024)

Company Filing History:

12 out of 45

Aurigene Discovery Technologies Limited

patents

6 out of 19

Aurigene Oncology Limited

Eisai R&d Management Co., Ltd.

patents

6. 1 out of 4,517

Eli Lilly and Company

patents

7. 1 out of 8

Olema Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

SMARCA Degraders

CDK Inhibitors

IRAK4 Inhibitors

Bromodomain Inhibitors

Acylsulfonamide

Heterocyclic Derivatives

Hematological Disorders

Pyrazolo Derivatives

Tetrasubstituted Alkenes

Compounds and Compositions

KAT6A Inhibitors

Chk1 Inhibitors

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12570650 - 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders (2026-03-10),

2. 12428379 - Acylsulfonamide KAT6A inhibitors (2025-09-30),

3. 12410193 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2025-09-09),

4. 12371426 - Pyridazine derivatives as SMARCA2/4 degraders (2025-07-29),

5. 12331023 - Substituted heterocyclyl derivatives as CDK inhibitors (2025-06-17),

6. 11981685 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2024-05-14),

7. 11865114 - Method for treating diseases using SMARCA2/4 degraders (2024-01-09),

8. 11691987 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2023-07-04),

9. 11419875 - Compounds and compositions for treating hematological disorders (2022-08-23),

10. 11186576 - Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors (2021-11-30),

11. 11174232 - Substituted heterocyclyl derivatives as CDK inhibitors (2021-11-16),

12. 10995100 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2021-05-04),

13. 10894786 - Substituted pyrazole derivatives as selective CDK12/13 inhibitors (2021-01-19),

14. 10851065 - Tetrasubstituted alkene compounds and their use (2020-12-01),

15. 10689347 - Substituted heterocyclyl derivatives as CDK inhibitors (2020-06-23),

Title: Inventor Susanta Samajdar

Introduction: Susanta Samajdar is a renowned inventor based in Bengaluru, India, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Susanta Samajdar holds several patents in various technological domains, including artificial intelligence, machine learning, and renewable energy solutions.

Career Highlights: With a career spanning over two decades, Susanta Samajdar has worked with leading tech companies and research institutions, consistently pushing the boundaries of innovation. His work has been instrumental in shaping the future of technology.

Collaborations: Throughout his career, Susanta Samajdar has collaborated with top researchers, engineers, and scientists from around the world, fostering a culture of innovation and knowledge sharing.

Conclusion: Susanta Samajdar's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and researchers.

Profile summary based on public USPTO records.